Supporters see daraxonrasib as a rare breakthrough against a cancer that is usually detected late and has resisted treatment for decades. The approval offers patients a potentially longer survival window, while clinicians and regulators still face questions about side effects, affordability and how durable the benefit will be.

The US Food and Drug Administration approved the daily pill, sold as Rasonque by Revolution Medicines, after a 500-patient late-stage trial found that people with metastatic pancreatic cancer lived a median 13.2 months on daraxonrasib, compared with roughly 6.6 to 6.7 months on chemotherapy.¹ That difference amounts to nearly a doubling of survival in a disease with a five-year overall survival rate of just 13%.

The drug targets mutated KRAS proteins, which help drive tumor growth in more than 90% of pancreatic cancer cases. For years, the mutation was considered difficult to target because its structure gave medicines little to bind to. Daraxonrasib uses a molecular “glue” to attach to multiple KRAS subtypes, a strategy that doctors hope could open the door to further treatments.

The FDA called the medicine a “critical new option for patients facing an extraordinarily difficult and historically hard-to-treat cancer.”¹ Regulators approved it more than six months ahead of schedule, citing “unprecedented results in an area of high unmet need.”¹ The agency’s acting commissioner, Kyle Diamantas, framed the decision as a matter of speed: “It is our fundamental duty to deliver more cures and meaningful treatments to patients as quickly as possible.”²

Yet the results are not a clean victory. About 44% of patients taking daraxonrasib experienced severe side effects, including rash, diarrhea, nausea, fatigue and vomiting—lower than the 57.5% recorded among chemotherapy patients, but still substantial.¹ The trial was funded by the manufacturer, and longer-term survival remains unknown. For now, daraxonrasib is both a meaningful advance and a reminder of how much ground pancreatic cancer research still has to cover.